Crizotinib Combined With Bevacizumab as First-line Therapy in Metastatic Lung Adenocarcinoma Cancer With ALK Translocation or MET Amplification or ROS1 Translocation (CAMAR)
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Bevacizumab (Primary) ; Crizotinib (Primary)
- Indications Adenocarcinoma; Lung cancer
- Focus Therapeutic Use
- Acronyms CAMAR
- 02 Nov 2016 New trial record